Skip to main content

Fiscal Wizard · Single-issue tearsheet

ATNM / Jun 21, 2026 Run #7408

ATNM

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Composite verdict

F 8.9 / 100
Bearish setup · Oscillator 6 drivers · 3 gates blocking
  • Rate of Change
  • Aroon Oscillator
  • Accumulation/Distribution Line
Consider long put target Δ ~0.60 · ~35 DTE Bearish setup, Grade B → ITM put target

Industry rank 459th of 598 in Biotechnology

rescore-sweep
Technical synthesis
Bull 0%Evidence: High · 22 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 49

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

16.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EV/Sales 75
Free Cash Flow Yield 0
FCF Margin 0
EBITDA Margin 0

Technicals Bearish

1.1 / 100

Bearish setup leads (Rate of Change, Aroon Oscillator, Accumulation/Distribution Line); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 10
Aroon Oscillator 17
Accumulation/Distribution Line 20

Risk Gates

3 blocking 7 caution

3 guards active, 18 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ATNM.